Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Omnicell (OMCL) stocks in Canada

Learn how to easily invest in Omnicell stocks.

Omnicell Inc
- $0.65 ( - 0.58%)

Omnicell (OMCL) is a leading health information services business based in the US. It opened the day at $152.43 after a previous close of $151.5. During the day the price has varied from a low of $150.03 to a high of $153.13. The latest price was $151.24 (25 minute delay). Omnicell is listed on the NASDAQ and employs 3,800 staff. All prices are listed in US Dollars.

How to buy stocks in Omnicell

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OMCL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Omnicell stock price (NASDAQ:OMCL)

Use our graph to track the performance of OMCL stocks over time.

Omnicell shares at a glance

Information last updated 2021-07-09.
Previous close$151.50
Change $-0.26
Change % -0.1716%
Volume 195,046
Information last updated 2022-05-11.
52-week range$104.32 - $187.29
50-day moving average $125.26
200-day moving average $152.28
Wall St. target price$167.44
PE ratio 70.9946
Dividend yield $0 (0%)
Earnings per share (TTM) $1.49

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Omnicell stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Omnicell price performance over time

Historical closes compared with the close of $151.24 from 2022-05-13

1 week (2022-05-06) 31.05%
1 month (2022-04-12) N/A
3 months (2022-02-16) 13.01%
6 months (2021-11-16) -15.95%
1 year (2021-05-14) 14.65%
2 years (2020-05-15) 141.48%
3 years (2019-05-16) 86.30%
5 years (2017-05-16) 270.69%

Is Omnicell under- or over-valued?

Valuing Omnicell stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Omnicell's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Omnicell's P/E ratio

Omnicell's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 71x. In other words, Omnicell shares trade at around 71x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Omnicell's PEG ratio

Omnicell's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.28. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Omnicell's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Omnicell's EBITDA

Omnicell's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $137.6 million.

The EBITDA is a measure of a Omnicell's overall financial performance and is widely used to measure a its profitability.

Omnicell financials

Revenue TTM $1.2 billion
Operating margin TTM 7.3%
Gross profit TTM $555 million
Return on assets TTM 2.73%
Return on equity TTM 6.9%
Profit margin 6%
Book value $24.29
Market capitalisation $4.7 billion

TTM: trailing 12 months

Omnicell share dividends

We're not expecting Omnicell to pay a dividend over the next 12 months.

Omnicell share price volatility

Over the last 12 months, Omnicell's shares have ranged in value from as little as $104.32 up to $187.29. A popular way to gauge a stock's volatility is its "beta".

OMCL.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omnicell's is 1.1534. This would suggest that Omnicell's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Omnicell overview

Omnicell, Inc. , together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site